TICKERNERD
Menu
ZBIOZBIOHealthcare · Biotechnology

ZBIO Stock Forecast: Zenas BioPharma, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$31
+0.13% on the day

The 8 Wall Street analysts covering Zenas BioPharma, Inc. hold a median 12-month price target of $45 — +44.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 26 of 100 as at 12 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$2.0B
Ticker Nerd rank
26 / 100
Median analyst target
$45
Analysts covering
8
Revenue$1.0M
Operating income−$77.7M
Net income−$111.5M
Free cash flow−$87.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−5.4%
1M
−4.0%
YTD
−14.2%
1Y
+54.4%
From 52W high
−27.9%
From 52W low
+104.9%
$15
$43
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ZBIO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Zenas BioPharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
26 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
82
Volatility
60
Value
55
Accruals
44
Revisions
40
Size
36
Quality
29
Growth
27
Issuance
6

Momentum (82): The shares have been drifting up relative to others.

Issuance (6): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ZBIO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ZBIO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50$60Oct 25Jan 26Apr 26Jul 26ZBIOHigh $59Median $45Low $32

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
7 Buy1 Hold0 Sell
Low $32Median $45High $59

The green dot is the last close — the median target sits +44.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
14 Aug 2026GuggenheimReiteratesBuy$55
14 Aug 2026Morgan StanleyMaintainsEqual-Weight$22 → $32
14 Aug 2026WedbushReiteratesOutperform$45
15 May 2026HC Wainwright & Co.ReiteratesBuy$44
15 May 2026HC Wainwright & Co.ReiteratesBuy—
14 May 2026Morgan StanleyMaintainsEqual-Weight$21 → $22
14 May 2026Morgan StanleyMaintainsEqual-Weight—
17 Mar 2026CitigroupMaintainsBuy—
17 Mar 2026GuggenheimMaintainsBuy—
17 Mar 2026HC Wainwright & Co.ReiteratesBuy—
17 Mar 2026Morgan StanleyMaintainsEqual-Weight—
10 Feb 2026HC Wainwright & Co.ReiteratesBuy—
6 Jan 2026Morgan StanleyDowngradeEqual-Weight—
22 Dec 2025WedbushReiteratesOutperform—
26 Nov 2025Evercore ISI GroupInitiatesOutperform—
13 Nov 2025Morgan StanleyMaintainsOverweight—
28 Oct 2025CitigroupMaintainsBuy—
28 Oct 2025HC Wainwright & Co.MaintainsBuy—
28 Oct 2025Morgan StanleyMaintainsOverweight—
9 Oct 2025HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ZBIO appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ZBIO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Zenas BioPharma, Inc. returned +54.4% against +17.5% for the S&P 500, dividends included.

ZBIO vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200Oct 25Jan 26Apr 26Jul 26ZBIOS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ZBIO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
2
Fundamentals

Zenas BioPharma, Inc. (ZBIO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
1.6×

Cheaper than 70% of US stocks

Price / sales
2028.3×

Cheaper than 1% of US stocks

Price / book
8.0×

Cheaper than 12% of US stocks

EV / EBITDA
−6.1×

Cheaper than 81% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
−100.0%

Higher than 1% of US stocks

Gross margin
—
Operating margin
−7765.9%

Higher than 2% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−199.0%

Higher than 7% of US stocks

Return on assets
−34.4%

Higher than 12% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Zenas BioPharma, Inc. (ZBIO) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Zenas BioPharma, Inc. has a market value of $2.0B and an enterprise value of $1.7B.

  • Revenue in the twelve months to 30 June 2026: $1.0M.

  • Net income over the same four quarters: −$484.4M, a −48438.4% net margin.

  • Diluted earnings per share, trailing twelve months: $−8.99.

  • Free cash flow in the twelve months to 30 June 2026: −$291.0M.

  • Shares outstanding: 63.3M.

  • Trailing P/E: 1.6×; forward P/E: −6.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.03%, paying out 0% of earnings.

  • Zenas BioPharma, Inc. employs 167 people — $6K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

ZBIO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ZBIOZenas BioPharma, Inc.$2.0B
26
AGIOAgios Pharmaceuticals, Inc.$2.0B
82
KODKodiak Sciences, Inc.$2.0B
43
VCELVericel Corp.$1.9B
94
GENBGenerate Biomedicines, Inc.$2.0B
1
RAPPRapport Therapeutics, Inc.$2.0B
46
ZYMEZymeworks, Inc.$1.9B
77

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Zenas BioPharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ZBIO news & analysis

Zenas BioPharma, Inc. (ZBIO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Seeking Alpha · 10 Sept 2026neutral

Zenas BioPharma, Inc. (ZBIO) presented at Citigroup's Biopharma Back to School Summit 2026, with a transcript of the presentation published by Seeking Alpha. The item reports the company's participation in the conference event.

Why it matters — A ZBIO watcher would care because the presentation transcript offers insight into the company's positioning and messaging at a major biopharma investor conference.

Zenas BioPharma to Host Obexelimab IgG4-RD Investor Event

GlobeNewsWire · 8 Sept 2026neutral

Zenas BioPharma announced it will host a virtual Obexelimab IgG4-RD Investor Event on Tuesday, September 29, 2026, from 8:00–9:30 a.m. ET. The clinical-stage biopharmaceutical company focuses on therapies for autoimmune and inflammatory diseases.

Why it matters — Investors following ZBIO will be able to hear directly about the company's obexelimab program for IgG4-related disease at the upcoming investor event.

Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences

GlobeNewsWire · 4 Sept 2026neutral

Zenas BioPharma announced that management will present at upcoming healthcare investor conferences, beginning with the Citi Biopharma Back to School Conference on September 9, 2026 at 4:20 p.m. The company, which focuses on therapies for autoimmune and inflammatory diseases, is listed on Nasdaq under the ticker ZBIO.

Why it matters — The presentations offer ZBIO watchers an opportunity to hear directly from management about the company's clinical-stage pipeline and strategy at prominent investor events.

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 18 Aug 2026neutral

Zenas BioPharma announced that on August 17, 2026, its Compensation Committee granted an aggregate of 11,000 restricted stock units to newly hired employees as an inducement to their employment, in accordance with Nasdaq Listing Rule 5635(c)(4).

Why it matters — The grant signals new hires joining the company and reflects standard equity-based compensation practices that ZBIO watchers may note as part of the company's talent and incentive structure.

Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update

GlobeNewsWire · 13 Aug 2026positive

Zenas BioPharma reported its second quarter 2026 financial results and corporate update, noting that its obexelimab BLA submission for IgG4-RD was accepted by the FDA with a PDUFA date of May 27, 2027. The company also reported ongoing trials for obexelimab and ZB021, board changes, and cash, cash equivalents and investments of $673.9 million as of June 30, 2026.

Why it matters — The FDA acceptance of the obexelimab BLA with a set PDUFA target date marks a key regulatory milestone for Zenas' lead candidate, while upcoming Phase 2 topline results and a strong cash position provide clarity on near-term catalysts.

FAQ

Frequently asked questions about ZBIO stock

What is the ZBIO stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Zenas BioPharma, Inc. have a median 12-month price target of $45, with estimates ranging from $32 to $59. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ZBIO stock a buy right now?

Of the 8 analysts covering Zenas BioPharma, Inc., 7 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Zenas BioPharma, Inc. 26 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ZBIO?

As at 12 Sept 2026, Zenas BioPharma, Inc. ranks 26 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (82 of 100).

Will ZBIO stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +44.5% from the last close, and Ticker Nerd's factor model ranks Zenas BioPharma, Inc. 26 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ZBIO stock forecast for 2030?

No analyst covering Zenas BioPharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ZBIO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $32 to $59 over the next 12 months.

How has ZBIO stock performed over the past year?

Zenas BioPharma, Inc. returned +54.4% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Zenas BioPharma, Inc. do?

Zenas BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing immunology-based therapies for autoimmune and inflammatory diseases.

What is the latest news on ZBIO?

The most recent item we track (Seeking Alpha, 10 Sept 2026): "Zenas BioPharma, Inc. (ZBIO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript". Zenas BioPharma, Inc. (ZBIO) presented at Citigroup's Biopharma Back to School Summit 2026, with a transcript of the presentation published by Seeking Alpha. The item reports the company's participation in the conference event.

Company

About Zenas BioPharma, Inc.

Zenas BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing immunology-based therapies for autoimmune and inflammatory diseases. The company’s lead program is obexelimab, a bifunctional monoclonal antibody being studied across multiple immune-mediated conditions, including IgG4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Zenas BioPharma also advances a broader pipeline of antibody-based and targeted therapies aimed at modulating immune pathways involved in chronic autoimmune disorders. Based in Waltham, Massachusetts, the company operates as a research-driven drug developer with current activities centered on clinical development, regulatory progress, and building a portfolio of therapies for patients with significant unmet medical needs.

CEO Mr. Leon Oliver Moulder Jr., M.B.A. · 167 employees · United States · https://zenasbio.com